Skip to main content
Clinical Trials/CTRI/2025/07/090149
CTRI/2025/07/090149
Not yet recruiting
Phase 3 4

COMPARATIVE EVALUATION OF CLINICAL AND RADIOGRAPHICAL SUCCESS IN MINERAL TRIOXIDE AGGREGATE, BIOCERAMIC AND NANOHYRDROXYAPATITE AS PULPOTOMY MEDICAMENT IN PRIMARY MOLARS - A RANDOMIZED CONTROLLED TRIAL

Not provided1 site in 1 country45 target enrollmentStarted: August 1, 2025Last updated:

Overview

Phase
Phase 3 4
Status
Not yet recruiting
Enrollment
45
Locations
1
Primary Endpoint
All cause morbidity at 3 months. Success rate of pulpotomy at 3 months (defined as absence of clinical symptoms and radiographic signs of pathology).

Overview

Brief Summary

This randomized controlled trial compared the clinical and radiographic success of three pulpotomy medicaments in primary molars: Mineral Trioxide Aggregate (MTA), Bioceramic Putty, and Nano-Hydroxyapatite (nHA). Personal, medical, and dental histories were collected from all participants. Preoperative diagnostic radiographs were taken using RVG. The pulpotomy procedure involved local anesthesia, rubber dam isolation, complete caries removal, and coronal pulp amputation under sterile conditions. Hemostasis was achieved with saline and a moistened cotton pellet. The assigned medicament was then applied over the radicular pulp: MTA for Group I, Bioceramic Putty for Group II, and nHA for Group III. A zinc oxide eugenol base was placed over the medicament, and the tooth was restored with a stainless steel crown. Follow-up evaluations were conducted at 1, 3, and 6 months to assess clinical and radiographic outcomes.

The study aims to explore viable alternatives to MTA, which is considered the gold standard. Bioceramic materials may offer advantages such as easier handling, quicker setting time, and cost-effectiveness. nHA, due to its bioactivity and regenerative potential, could provide a more biocompatible option. These alternatives could enhance the accessibility of pulpotomy treatment, especially in low-resource areas. The findings contribute to evidence-based pediatric endodontics and support the continued development of innovative dental biomaterials. Effective pulpotomy medicaments help in maintaining arch length, supporting proper eruption of permanent teeth, and minimizing the need for invasive treatments.

Study Design

Study Type
Interventional
Allocation
Randomized
Masking
Participant and Outcome Assessor Blinded

Eligibility Criteria

Ages
4.00 Year(s) to 9.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • Primary molars with deep caries lesion without spontaneous pain Vital carious pulp exposures that bleed upon entering the pulp chamber Tooth with at least two thirds of root length.

Exclusion Criteria

  • Medically compromised patients and uncooperative patients.
  • Children whose parents who did not give the consent.
  • Teeth shows the signs and symptoms of abscess, fistula, sinus tract and mobility.
  • Periapical pathology and calcifications in the canal were excluded from the trial.

Outcomes

Primary Outcomes

All cause morbidity at 3 months. Success rate of pulpotomy at 3 months (defined as absence of clinical symptoms and radiographic signs of pathology).

Time Frame: at baseline, 1 month, 3 months and 6 month

Secondary Outcomes

  • All cause morbidity at 1, 3 and 6 months. Incidence of post-operative pain and patient satisfaction by Five point likert scale.(at baseline, 1 month, 3 months and 6 month)

Investigators

Sponsor
Not provided
Responsible Party
Principal Investigator
Principal Investigator

ELANCHEZHIYAN P

Adhiparasakthi dental college and hospital

Study Sites (1)

Loading locations...

Similar Trials